⌘K
t
On January 2, 2026, GSK plc President, Corporate Development, David Redfern, and SVP & Company Secretary, Victoria Whyte, each acquired 790 Ordinary Shares. These acquisitions, conducted on the London Stock Exchange, resulted from exercising options granted on November 28, 2022, at an option price of £11.39 per Ordinary Share under the Company's Share Save Plan.
| Date | 5 Jan 2026 |
| Time | 15:30:00 |
| Category | Director/PDMR dealings |
| ID | 6963N |
GSK plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
David Redfern |
|||
|
b) |
Position/status |
President, Corporate Development |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the exercise of options granted on 28 November 2022 at the option price of £11.39 per Ordinary Share under the Company's Share Save Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£11.39 |
790 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-01-02 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Victoria Whyte |
|||
|
b) |
Position/status |
SVP & Company Secretary |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the exercise of options granted on 28 November 2022 at the option price of £11.39 per Ordinary Share under the Company's Share Save Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£11.39 |
790 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-01-02 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG